Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2

European Journal of Pharmacology(2024)10.1016/j.ejphar.2024.177231Source: DataRank Database

Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2 is a research paper published in European Journal of Pharmacology (2024). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

3 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.53)OA: closedTopics (42)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Bing-Huan Lin,Megumi Murakami ORCID,Yu‐Shan Wu ORCID,Tai‐Ho Hung ORCID,Suresh V. Ambudkar ORCID

Live enrichment

PubMed:39725134 OpenAlex:https://openalex.org/W4405739170

Taichung Veterans General Hospital

Grant: TCVGH-T1137809

Chang Gung Memorial Hospital

Grant: BMRPC17

Chang Gung Memorial Hospital

Grant: CMRPD1N0121

Chang Gung Memorial Hospital

Grant: CMRPD1M0582

National Science and Technology Council

Grant: 112-2314-B-182A-061-MY3

National Science and Technology Council

Grant: 112-2320-B-182-018

National Institutes of Health

National Cancer Institute

Kaohsiung Veterans General Hospital

FWCI

0.53

Citation Percentile

0.7%

Citation Trend

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S001429992400921X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S001429992400921X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ejphar.2024.177231

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39725134

Fields of Study

Drug Transport and Resistance MechanismsCancer therapeutics and mechanismsCholangiocarcinoma and Gallbladder Cancer StudiesHumansATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, NeoplasmNeoplasm ProteinsATP Binding Cassette Transporter, Subfamily BDrug Resistance, MultipleCell Line, TumorAntineoplastic AgentsApoptosisProtein Kinase Inhibitors

MeSH Terms

ATP Binding Cassette Transporter, Subfamily G, Member 2Antineoplastic AgentsHumansNeoplasm ProteinsApoptosisDrug Resistance, MultipleATP Binding Cassette Transporter, Subfamily BDrug Resistance, NeoplasmCell Line, TumorProtein Kinase Inhibitors

Keywords

Abcg2EffluxMultiple drug resistancePharmacologyDrugDrug resistanceMedicineCancerChemistryBiologyATP-binding cassette transporterInternal medicineTransporterMicrobiologyBiochemistryMultidrug resistanceAbcb1Drug RepositioningVodobatinib

Sustainable Development Goals

SDG 0: Good health and well-being

Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2

FAIR Checklist

Authors (7)

Funding (9 grants)

Impact

Open Access

Topics